Skip to main content

Alaunos Therapeutics, Inc.

TCRT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001107421

No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Alaunos Therapeutics, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of TCRT: Q1 2026 compared with Q2 2026
MeasureQ1 2026Of which not filed for Q2 2026Q2 2026Change
Holders29229+2
Shares125.9K1890.4K−35.5K (−28.2%)
Value$360.5K$52$204.4K−$156.1K (−43.3%)

2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to TCRT in Q2 2026
InstitutionSharesValue% of portfolio
SRS Capital Advisors, Inc.1,216$2.75K0.00%
Bokf, NA66$1490.00%
Axiom Investment Management LLC46$1040.00%
Barclays PLC15$340.00%
West Paces Advisors Inc.10$230.00%
IFG Advisory, LLC6$140.00%

Sold out (4)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of TCRT in Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
HRT Financial LP13,327$38.0K
Two Sigma Investments, LP10,839$31.0K
XTX Topco Ltd10,174$29.1K
Citigroup Inc1$3

Not filed for Q2 2026 yet (2)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TCRT in Q1 2026 that haven't filed for Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
Sunbelt Securities, Inc.10$29
CWM, LLC8$23